AxoGen, Inc.
AXGN
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosā¦ read more
Healthcare
Medical Devices
38 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$23.57
Price-1.75%
-$0.42
1Y
Price
Market Cap
$1.084b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years+7.7%
EBITDA Margin+1.0%
Net Profit Margin+12.4%
Free Cash Flow MarginRevenue
$203.271m
+8.5%
1y CAGR+13.7%
3y CAGR+12.5%
5y CAGREarnings
-$4.663m
+53.2%
1y CAGR+44.1%
3y CAGR+31.3%
5y CAGREPS
-$0.11
+52.2%
1y CAGR+44.4%
3y CAGR+31.8%
5y CAGRBook Value
$112.276m
$205.453m
Assets$93.177m
Liabilities$68.188m
DebtDebt to Assets
33.2%
6.3x
Debt to EBITDAFree Cash Flow
$5.538m
+50245.5%
1y CAGR+16796.7%
3y CAGR+12600.2%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company